Every article, report, and earnings note where FMS appears.
Fresenius Medical Care is a Hold as improving margins and cost savings offset sluggish revenue growth and looming reimbursement pressure. The dialysis leader’s 5008X rollout and clinic rationalization support earnings, but the stock already sits near fair value.
Fresenius Medical Care AG & Co. KGaA (FMS) falls after first-quarter results sparked a sharp selloff. Investors focused on weaker U.S. treatment volumes, reported profit declines, and restructuring costs, even as adjusted earnings improved and full-year guidance was reaffirmed.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate FMS ReportCancel anytime